FDA Approves Pembrolizumab for PD-L1-Positive Ovarian Cancer
Episode Summary
FDA approves pembrolizumab combinations for PD-L1–positive, platinum-resistant ovarian cancer, improving progression-free and overall survival, offering new hope for patients with limited treatment options.